Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Liu

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 14, 2018
Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapyMaria Thor, Andrew Jackson, Michael J Zelefsky, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2006
Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapyHoward Huaihan Pai, Charles Ludgate, Tom Pickles, et al.
International Journal of Radiation Oncology, Biology, Physics|December 30, 2008
Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patientsMira Keyes, Stacy Miller, Veronika Moravan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2010
Incorporating quantitative single photon emission computed tomography into radiation therapy treatment planning for lung cancer: impact of attenuation and scatter correction on the single photon emission computed tomography-weighted mean dose and functional lung segmentationLingshu Yin, Sergey Shcherbinin, Anna Celler, et al.
Brachytherapy|July 19, 2011
Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patientsMira Keyes, Ingrid Spadinger, Mitchell Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
The impact of peer review of volume delineation in stereotactic body radiation therapy planning for primary lung cancer: a multicenter quality assurance studyAndrea C Lo, Mitchell Liu, Elisa Chan, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2026
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical TrialCurtis Leclerc, Sarah Baker, Will Jiang, et al.
BMC Cancer|April 23, 2026
Re-evaluating previous dose and allowing increasing recovery (REPAIR): study protocol for a thoracic reirradiation phase I dose escalation trialDonna H Murrell, Nicolaus Andratschke, Alanah M Bergman, et al.
BMC Cancer|July 25, 2012
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trialDavid A Palma, Cornelis J A Haasbeek, George B Rodrigues, et al.
International Journal of Radiation Oncology, Biology, Physics|August 25, 2022
A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic DiseaseJina Kim, Jee Suk Chang, Wonmo Sung, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 14, 2018
Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapyMaria Thor, Andrew Jackson, Michael J Zelefsky, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2006
Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapyHoward Huaihan Pai, Charles Ludgate, Tom Pickles, et al.
International Journal of Radiation Oncology, Biology, Physics|December 30, 2008
Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patientsMira Keyes, Stacy Miller, Veronika Moravan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2010
Incorporating quantitative single photon emission computed tomography into radiation therapy treatment planning for lung cancer: impact of attenuation and scatter correction on the single photon emission computed tomography-weighted mean dose and functional lung segmentationLingshu Yin, Sergey Shcherbinin, Anna Celler, et al.
Brachytherapy|July 19, 2011
Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patientsMira Keyes, Ingrid Spadinger, Mitchell Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
The impact of peer review of volume delineation in stereotactic body radiation therapy planning for primary lung cancer: a multicenter quality assurance studyAndrea C Lo, Mitchell Liu, Elisa Chan, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2026
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical TrialCurtis Leclerc, Sarah Baker, Will Jiang, et al.
BMC Cancer|April 23, 2026
Re-evaluating previous dose and allowing increasing recovery (REPAIR): study protocol for a thoracic reirradiation phase I dose escalation trialDonna H Murrell, Nicolaus Andratschke, Alanah M Bergman, et al.
BMC Cancer|July 25, 2012
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trialDavid A Palma, Cornelis J A Haasbeek, George B Rodrigues, et al.
International Journal of Radiation Oncology, Biology, Physics|August 25, 2022
A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic DiseaseJina Kim, Jee Suk Chang, Wonmo Sung, et al.
Pageof 10